Threshold Pharmaceuticals Inc. (THLD): Today's Featured Drugs Winner
Threshold Pharmaceuticals (THLD) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 1.3%. By the end of trading, Threshold Pharmaceuticals rose 26 cents (3.8%) to $7.20 on average volume. Throughout the day, 2.8 million shares of Threshold Pharmaceuticals exchanged hands as compared to its average daily volume of 2.5 million shares. The stock ranged in a price between $6.68-$7.32 after having opened the day at $6.88 as compared to the previous trading day's close of $6.94. Other companies within the Drugs industry that increased today were: AspenBio Pharma (APPY), up 21.9%, Zogenix (ZGNX), up 15.7%, Ampio Pharmaceuticals (AMPE), up 11.7%, and Opexa Therapeutics (OPXA), up 8.9%. Threshold Pharmaceuticals, Inc., a development stage company, focuses on the discovery and development of drugs for the microenvironment of solid tumors and the bone marrows of hematologic malignancies as novel treatments for patients living with cancer. Threshold Pharmaceuticals has a market cap of $370.6 million and is part of the health care sector. Shares are up 468.9% year to date as of the close of trading on Tuesday. Currently there are three analysts that rate Threshold Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold. TheStreet Ratings rates Threshold Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and deteriorating net income.
- You can view the full Threshold Ratings Report.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
Latest Headlines about THLD
-
10 ASCO '13 Abstracts You Can Read Right Now
06:00PM 05/15/13
-
5 Stocks Poised for Breakouts
02:39PM 03/01/13
-
4 Biotech Stocks Under $10 Moving Higher
09:41PM 02/20/13
-
3 Biotech Stocks Under $10 Moving Higher
02:51PM 02/12/13
-
Stocks Continue to Climb as Companies Exceed Expectations
04:51PM 01/25/13
-
Biotech Stock Mailbag: Keryx, Sangamo, Threshold and Amarin
07:00AM 01/25/13
-
Celgene's Abraxane: Two Month Survival Boost In Pancreatic Cancer Trial
06:22PM 01/22/13
Latest from TheStreet Wire
-
Axis Capital Holdings Ltd (AXS): Today's Featured Insurance Laggard
05:01PM 05/17/13
-
Validus Holdings Inc. (VR): Today's Featured Financial Laggard
05:01PM 05/17/13
-
Cavium Inc (CAVM): Today's Featured Electronics Laggard
05:01PM 05/17/13
-
Smithfield Foods Inc. (SFD): Today's Featured Consumer Goods Laggard
05:01PM 05/17/13
-
Autodesk Inc. (ADSK): Today's Featured Computer Software & Services Laggard
05:01PM 05/17/13
-
Goldcorp Inc. (GG): Today's Featured Basic Materials Laggard
05:01PM 05/17/13
-
Finisar Corporation (FNSR): Today's Featured Technology Laggard
05:01PM 05/17/13
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
